Biofrontera (BFRI) vs InMed Pharmaceuticals (INM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Biofrontera is the larger company by market cap ($13.6 million vs $7.3 million), about 1.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BFRI | INM |
|---|---|---|
| Share price | $0.9188 | $1.33 |
| Market cap | $13.65M | $7.31M |
| 1-day change | -1.77% | 0.00% |
| YTD return | +61.19% | — |
| 1-year return | -9.03% | — |
| Forward P/E | 2.14 | — |
| EPS (TTM) | $-0.43 | $-2.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.66 | $2.40 |
| 52-week low | $0.555 | $0.575 |
| Distance from 52-week high | -44.65% | -44.58% |
| Analyst consensus | none | — |
| Avg. price target upside | +553.03% | — |
| Average volume | 547.45K | 914.23K |
| Shares outstanding | 14.85M | 5.49M |
| Employees | 84 | 6 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Biofrontera
BFRI stock →Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions.
Healthcare · Drug Manufacturers - Specialty & Generic · 84 employees
About InMed Pharmaceuticals
INM stock →InMed Pharmaceuticals Inc. operates as a pharmaceutical drug development company in the United States.
Healthcare · Drug Manufacturers - Specialty & Generic · 6 employees
BFRI vs INM FAQ
Which is bigger, Biofrontera or InMed Pharmaceuticals?
Biofrontera (BFRI) is larger, with a market capitalization of $13.65M compared with $7.31M for InMed Pharmaceuticals (INM).
Are Biofrontera and InMed Pharmaceuticals in the same industry?
Yes. Both are classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.